HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zuo, L. Articles by Hirsch, R. Search for Related Content PubMed PubMed Citation Articles by Zuo, L. Articles by Hirsch, R. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Autoimmune Diseases Joint Disorders

A Single-Chain Class II MHC-IgG3 Fusion Protein Inhibits Autoimmune Arthritis by Induction of Antigen-Specific Hyporesponsiveness¹

Li Zuo^*, Constance M. Cullen^*, Monica L. DeLay^*, Sherry Thornton^*, Linda K. Myers, Edward F. Rosloniec, Gregory P. Boivin and Raphael Hirsch^*,2

^* Division of Rheumatology, Children’s Hospital Medical Center, and Division of Comparative Pathology, University of Cincinnati, Cincinnati, OH 45229; and Department of Pediatrics, University of Tennessee, and Veterans Affairs Medical Center, Memphis, TN 38163

T cells play a central role in many autoimmune diseases. A method to specifically target the function of autoreactive T cell clones would avoid the global immunosuppression associated with current therapies. To develop a molecule capable of inhibiting autoreactive T cell responses in vivo, single-chain peptide-I-A-IgG3 fusion proteins were constructed and expressed in both mammalian and insect cells. The fusion proteins were designed with an IgG3 Fc moiety to make them divalent, allowing TCR cross-linking, while lacking FcR binding and costimulation. The fusion proteins stimulated T cell hybridomas in vitro in a peptide-specific, MHC-restricted manner but failed to do so in soluble form. In vivo administration of an I-A^q fusion protein, containing an immunodominant collagen II peptide, significantly delayed the onset and reduced the severity of collagen-induced arthritis in DBA/1 mice by induction of Ag-specific hyporesponsiveness. Such fusion proteins may be useful to study novel therapeutic approaches for T cell-mediated autoimmune diseases.

This article has been cited by other articles:

				L. Li, Z. Yi, B. Wang, and R. Tisch Suppression of Ongoing T Cell-Mediated Autoimmunity by Peptide-MHC Class II Dimer Vaccination J. Immunol., October 1, 2009; 183(7): 4809 - 4816. [Abstract] [Full Text] [PDF]

				B. Dzhambazov, K. S. Nandakumar, J. Kihlberg, L. Fugger, R. Holmdahl, and M. Vestberg Therapeutic Vaccination of Active Arthritis with a Glycosylated Collagen Type II Peptide in Complex with MHC Class II Molecules J. Immunol., February 1, 2006; 176(3): 1525 - 1533. [Abstract] [Full Text] [PDF]

				Z. Karabekian, S. D. Lytton, P. B. Silver, Y. V. Sergeev, J. P. Schneck, and R. R. Caspi Antigen/MHC Class II/Ig Dimers for Study of Uveitogenic T Cells: IRBP p161-180 Presented by both IA and IE Molecules Invest. Ophthalmol. Vis. Sci., October 1, 2005; 46(10): 3769 - 3776. [Abstract] [Full Text] [PDF]

				E. L. Masteller, M. R. Warner, W. Ferlin, V. Judkowski, D. Wilson, N. Glaichenhaus, and J. A. Bluestone Peptide-MHC Class II Dimers as Therapeutics to Modulate Antigen-Specific T Cell Responses in Autoimmune Diabetes J. Immunol., November 15, 2003; 171(10): 5587 - 5595. [Abstract] [Full Text] [PDF]